Table 2.

Odds ratio of hepatitis B virus infection for liver fibrosis in metabolic dysfunction-associated fatty liver disease population.

	Crude		Model 1		Model 2
	OR (95% CI)	P-value	OR (95% CI)	P-value	OR (95% CI)	P-value
Severe steatosis
MAFLD	Ref		Ref		Ref
MAFLD + HBV	0.298 (0.152–0.586)	< 0.001	0.293 (0.148–0.578)	< 0.001	0.251 (0.117–0.542)	< 0.001
Ballooning
MAFLD	Ref		Ref		Ref
MAFLD + HBV	0.200 (0.096–0.415)	< 0.001	0.202 (0.097–0.423)	< 0.001	0.119 (0.049–0.294)	< 0.001
Active inflammation
MAFLD	Ref		Ref		Ref
MAFLD + HBV	1.981 (1.067–3.678)	0.03	1.972 (1.060–3.666)	0.032	1.803 (0.925–3.514)	0.083
Liver fibrosis
MAFLD	Ref		Ref		Ref
MAFLD + HBV	2.617 (1.358–5.044)	0.004	2.817 (1.438–5.518)	0.003	3.140 (1.479–6.663)	0.003

Model 1 adjusted for age and sex; Model 2 was adjusted for model 1 plus BMI, hypertension, type 2 diabetes mellitus, hypertriglyceridemia, hypercholesterolemia, hyperuricemia, high LDL-c, and low HDL-c.

MAFLD metabolic dysfunction-associated fatty liver disease, HBV hepatitis B virus, OR odds ratio, CI confidence interval.